Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 1 of 49 TITLE PAGE  
A PHASE 2, RANDOMIZED , DOUBLE -BLIND, PLACEBO -
CONTROLLED  STUDY OF THE SAFETY AND EFFICACY OF 
STI-5656 (ABIVERTINIB MALEATE) IN SUBJECTS 
HOSPITALIZED DUE TO  COVID -19 
 
STUDY INTERVENTION:  STI-5656  
PROTOCOL NUMBER:  STI-5656 -2001  
Version  5.0 
DATE FINAL:  07DEC 2020  
Amendment 1; V2.0  01JUL2020  
Amendment 2; V3.0  08JUL2020  
Amendment 3; V4.0  12NOV2020  
IND NUMBER:  151327  
SPONSOR NAME / ADDRESS:  
 Sorrento Therapeutics, Inc.  
4955 Directors Place,  
San Diego, CA 92121 USA  
 
CONFIDENTIAL  
This protocol is provided to you as an Investigator, potential Investigator, or consultant for review by 
you, your staff, and ethics committee/institutional review board.  The information contained in this 
document is regarded as confidential and, except to the extent necessary to obtain informed consent, 
may not be disclosed to another party unless such disclosure is required by law or regulations.  
Persons to whom the information is disclosed must be informed that the  information is confidential 
and may not be further disclosed by them.  
  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 2 of 49 MEDICAL MONITOR/ EMERGENCY CONTACT  
 
A PHASE 2, RANDOMIZED, DOUBLE -BLIND, PLACEBO -CONTROLLED STUDY OF 
THE SAFETY AND EFFICACY OF STI -5656 (ABIVERTINIB MALEATE) IN 
SUBJECTS HOSPITALIZE D DUE TO  COVID -19 
 
Role in Study  Name  Address and Telephone number  
Responsible Physician  Mike A. Royal  MD JD 
MBA  mroyal @Sorrentotherapeutics.com  
+1 (858) 204 1112  
 
  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 3 of 49  
SORRENTO THERAPEUTIC S INC. APPROVAL  
 
A PHASE 2, RANDOMIZED, DOUBLE -BLIND, PLACEBO -CONTROLLED STUDY OF 
THE SAFETY AND EFFICACY OF STI -5656 (ABIVERTINIB MALEATE) IN 
SUBJECTS HOSPITALIZED DUE TO  COVID -19 
 
   
07DEC 2020  
Signature of Responsible Officer   dd mmm yyyy  
Mike A. Royal MD JD MBA  
Chief Medical Officer, Sorrento Therapeutics, Inc.  
Printed Name of Responsible Officer and Title  
By my signature, I indicate I have reviewed this protocol and find its content to be 
acceptable.  
 

Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 4 of 49 SITE PRINCIPAL INVESTIGATOR SIGNATURE PAGE  
 
A PHASE 2, RANDOMIZED, DOUBLE -BLIND, PLACEBO -CONTROLLED STUDY OF 
THE SAFETY AND EFFICACY OF STI -5656 (ABIVERTINIB MALEATE) IN 
SUBJECTS HOSPITALIZED DUE TO  COVID -19 
 
 
 
   
Signature of Site Principal Investigator   dd mmm yyyy  
 
 
Printed Name of Site Principal Investigator  
Institution Name:  ______________________________________  
By my signature, I agree to personally supervise the conduct of this study at my study 
site and to ensure its conduct is in compliance with the protocol, informed consent, 
Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from  
Sorre nto Therapeutics Inc.  representatives, the Declaration of Helsinki, ICH Good 
Clinical Practices Guidelines, and local regulations governing the conduct of clinical 
studies.  
  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 5 of 49 TABLE OF CONTENTS  
TITLE PAGE  ................................ ................................ ................................ ................................ ...1 
MEDICAL MONITOR/ EMERGENCY CONTACT  ................................ ................................ .....2 
1. PROTOCOL SYNOPSIS  ................................ ................................ ........................... 11 
2. SCHEDULE OF ASSESSMENTS (SOA)  ................................ ................................ .15 
3. STUDY OBJECTIVES AND ENDPOINTS  ................................ .............................. 18 
3.1. Objectives  ................................ ................................ ................................ ................... 18 
3.1.1.  Prima ry Objective  ................................ ................................ ................................ .......18 
3.1.2.  Secondary Objectives  ................................ ................................ ................................ .18 
3.2. Endpoints  ................................ ................................ ................................ .................... 18 
3.2.1.  Primary  Endpoint  ................................ ................................ ................................ ........ 18 
3.2.2.  Secondary Endpoints  ................................ ................................ ................................ ..18 
3.2.3.  Exploratory Endpoints  ................................ ................................ ................................ 19 
4. INVESTIGATIONAL PLAN  ................................ ................................ ..................... 20 
4.1. Overall Study Design  ................................ ................................ ................................ ..20 
4.2. End of Trial Definition  ................................ ................................ ............................... 21 
5. SELECTION AND WITHDRAWAL OF SUBJECTS  ................................ .............. 22 
5.1. Subject Inclusion Criteria  ................................ ................................ ........................... 22 
5.2. Subject Exclusion Criteria  ................................ ................................ .......................... 23 
5.3. Screen Failures  ................................ ................................ ................................ ............ 23 
6. TREATMENT OF PARTICPANTS  ................................ ................................ .......... 25 
6.1. Description of Investigational Product  ................................ ................................ .......25 
6.2. Investigational Product Administration  ................................ ................................ ......25 
6.3. Stopping Rule Triggers  ................................ ................................ ............................... 25 
6.4. Dosing of Subjects Unable to Take Test Article PO  ................................ .................. 25 
6.5. Investigational Product Compliance  ................................ ................................ ........... 26 
6.6. Overdose  ................................ ................................ ................................ ..................... 26 
6.7. Randomization and Blinding  ................................ ................................ ...................... 26 
6.8. Emergency Unblinding  ................................ ................................ ............................... 26 
6.9. Concomitant Medications  ................................ ................................ ........................... 26 
6.9.1.  Prohibited Concomitant Medications  ................................ ................................ ......... 26 
7. IP MATERIALS AND MANAGEMENT  ................................ ................................ .27 
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 6 of 49 7.1. Investigational Product  ................................ ................................ ............................... 27 
7.2. IP Packaging and Labeling  ................................ ................................ ......................... 27 
7.3. IP Storage  ................................ ................................ ................................ .................... 28 
7.4. IP Accountability  ................................ ................................ ................................ ........ 28 
7.5. IP Handling and Disposal  ................................ ................................ ........................... 28 
8. STUDY PROCEDURES  ................................ ................................ ............................ 29 
8.1. Description of Procedures  ................................ ................................ ........................... 29 
8.1.1.  Informed Consent  ................................ ................................ ................................ .......29 
8.1.2.  RT-PCR assay for SARS -CoV -2 ................................ ................................ ................ 29 
8.1.3.  Collection of Demographics, Medical History, Prior and Concomitant 
Medications  ................................ ................................ ................................ ................. 29 
8.1.4.  Vital Signs  ................................ ................................ ................................ .................. 29 
8.1.5.  Physical Exam  ................................ ................................ ................................ ............ 30 
8.1.6.  12-lead Electrocardiogram (ECG)  ................................ ................................ .............. 30 
8.1.7.  Clinical laboratory tests  ................................ ................................ .............................. 30 
8.1.7.1.  Serum Chemistry  ................................ ................................ ................................ ........ 30 
8.1.7.2.  Hematology  ................................ ................................ ................................ ................. 30 
8.1.7.3.  Coagulation  ................................ ................................ ................................ ................. 30 
8.1.7.4.  C-reactive protein, serum ferritin, absolute lymphocyte count and cytokines  ........... 30 
8.1.7.5.  Urinalysis  ................................ ................................ ................................ .................... 30 
8.1.7.6.  Urine Pregnancy Test  ................................ ................................ ................................ .30 
8.1.8.  Respiratory Status  ................................ ................................ ................................ .......31 
8.1.9. Clinical status using 8 -category ordinal scale of patient health status  ....................... 31 
8.1.10.  IRT Registration, Randomization and Study Discontinuation or Completion.  .......... 31 
8.1.11.  Adverse Events  ................................ ................................ ................................ ........... 31 
8.1.12.  Follow -up contact  ................................ ................................ ................................ .......31 
8.2. Procedures by Study Day  ................................ ................................ ............................ 32 
8.2.1.  Screening  ................................ ................................ ................................ .................... 32 
8.2.2.  Study Day 1  ................................ ................................ ................................ ................ 32 
8.2.3.  Daily until Hospital Discharge  ................................ ................................ ................... 32 
8.2.4.  Hospital Discharge or Early Termination from Study  ................................ ................ 33 
8.2.5.  Outpatient Follow -up Day 28  ................................ ................................ ..................... 33 
8.2.6.  Telephone Follow -up Day 60  ................................ ................................ ..................... 33 
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 7 of 49 8.2.7.  Telephone Follow -up Day 90  ................................ ................................ ..................... 33 
8.3. Blood Volumes collected  ................................ ................................ ............................ 33 
9. STATISTICS  ................................ ................................ ................................ .............. 34 
9.1. Statistical Considerations  ................................ ................................ ............................ 34 
9.2. Sample Size Estimation  ................................ ................................ .............................. 34 
9.3. Analysis Population  ................................ ................................ ................................ ....34 
9.4. Data Analysis  ................................ ................................ ................................ .............. 34 
9.4.1.  Subject Disposition  ................................ ................................ ................................ .....34 
9.4.2.  Demographics and Baseline Characteristics  ................................ ............................... 34 
9.4.3.  Primary Endpoints  ................................ ................................ ................................ ......35 
9.4.4. Secondary Endpoints (Safety)  ................................ ................................ .................... 35 
9.4.5.  Secondary Endpoints (Efficacy)  ................................ ................................ ................. 35 
9.4.6.  Exploratory Endpoints  ................................ ................................ ................................ 36 
9.4.7.  Interim Analysis  ................................ ................................ ................................ .......... 36 
10. ADVERSE EVENT DEFINITIONS AND PROCEDURE FOR 
RECORDING, EVALUATING, FOLLOW -UP AND REPORTING  ....................... 37 
10.1.  Monitoring, Recording and Reporting of Adverse Events  ................................ ......... 37 
10.2.  Evaluation of Adverse Events  ................................ ................................ .................... 37 
10.2.1.  Seriousness  ................................ ................................ ................................ ................. 37 
10.2.2.  Severity / Intensity  ................................ ................................ ................................ ......38 
10.2.3.  Causality  ................................ ................................ ................................ ..................... 39 
10.2.4.  Duration  ................................ ................................ ................................ ...................... 39 
10.2.5.  Action Taken  ................................ ................................ ................................ .............. 39 
10.2.6.  Outcome  ................................ ................................ ................................ ...................... 40 
10.3.  Abnormal Laboratory Values  ................................ ................................ ..................... 40 
10.4.  Pregnancy  ................................ ................................ ................................ ................... 40 
10.4.1.  Females of Childbearing Potential ................................ ................................ .............. 40 
10.4.2.  Male Subjects  ................................ ................................ ................................ .............. 41 
10.5.  Reporting of Serious Adverse Events  ................................ ................................ ......... 41 
10.6.  Expedited Reporting of Adverse Events  ................................ ................................ .....41 
11. DIRECT ACCESS TO SOURCE DATA/DOCUMENTS ................................ ......... 43 
11.1.  Study Monitoring  ................................ ................................ ................................ ........ 43 
11.2.  Audits and Inspections  ................................ ................................ ................................ 43 
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 8 of 49 12. QUALITY CONTROL AND QUALITY ASSURANCE  ................................ ......... 45 
13. ETHICS  ................................ ................................ ................................ ...................... 46 
13.1.  Ethics Revie w ................................ ................................ ................................ ............. 46 
13.2.  Ethical Conduct of the Study  ................................ ................................ ...................... 46 
13.3.  Written Informed Consent  ................................ ................................ .......................... 46 
14. APPENDICES  ................................ ................................ ................................ ............ 47 
14.1.  List of Abbreviations and Definitions of Terms  ................................ ......................... 47 
14.2.  Ordinal Scale for Clinical Improvement ................................ ................................ .....49 
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 9 of 49 LIST OF TABLES  
Table  1: Schedule of Assessments  ................................ ................................ ............................ 15 
Table  3: Stopping Rule Triggers  ................................ ................................ ............................... 25 
Table  4: Abbreviations  ................................ ................................ ................................ .............. 47 
 
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 10 of 49 LIST OF FIGURES  
Figure  1: Study Design  ................................ ................................ ................................ ............... 14 
 
  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 11 of 49 1. PROTOCOL S YNOPSIS  
A Phase 2, Randomized , Double -Blind, Placebo -controlled  Study of the Safety and Efficacy of 
STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to  COVID -19 
Protocol Number:  STI-5656 -2001 , Version 4.0 
Investigator(s)/ Study Centers  
This study will be conducted at multiple  study cent ers located in the United States.   
Phase:  2 
Objectives  
Primary Objective:  
• To assess the efficacy of STI-5656  in subjects with severe coronavirus disease 2019 (COVID -
19) 
Secondary Objectives:  
• To assess the safety and tolerability of STI-5656  in subjects with severe COVID -19 
• To assess  the pharmacokinetic  profile  in the study population  
Endpoints  
Primary Endpoint:  
• Proportion of s ubject  alive and free of respiratory failure at Day 28 
Respiratory failure, is defined based on resource utilization of any of the following modalities:  
o Noninvasive positive pressure ventilation or continuous positive airway pressure  
o Endotracheal intubation and mechanical ventilation  
o Oxygen delivered by high -flow nasal cannula (heated, humidified, oxygen deli vered via 
reinforced nasal cannula at flow rates >20 L/min with fraction of delivered oxygen ≥0.5)  
o Extracorporeal membrane oxygenation (ECMO)  
Secondary Endpoints:   
• Types, frequencies, and severities of adverse events (AEs) and the relationships of AEs to IP; 
includes serious adverse events (SAEs)  
• Proportion of subjects alive and free of respiratory failure at Day 60 
• Change in clinical status (on a 0 -8-point ordinal s cale)1 of subject at Day 7, Day 14 and Day 28  
 
1 8-category ordinal scale of patient health status ranges:  0=no clinical or virological evidence of infection; 1=no 
limitation of activities; 2=limitation of activities; 3=hospitalized, no oxygen therapy; 4=oxygen by m ask or nasal 
prongs; 5=non -invasive ventilation or high -flow oxygen; 6=intubation and mechanical ventilation; 7=ventilation + 
additional organ support – pressors, rapid response team (RRT), extracorporeal membrane oxygenation (ECMO); 
8=death.   See Section  14.2 for form.  
 
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 12 of 49 • Proportion of subjects alive and discharged from Intensive Care Units (ICU) at Days 14 and 28  
• Time from randomization to first occurrence of respiratory failure or death on study due to any 
cause up to Day 28  
• Percent change from baseline in CRP at Days 3, 5, 7, 10, 14, 28  
• Relative change from baseline in oxygenation index (PaO2/FiO2) up to Day 5  
• All-cause mortality at Day 60 and Day 90  
• Number of days alive and free of respiratory failure at Day 28  
• Number of days with respiratory failure up to Day 28  
• Number of days hospitalized up to Day 28  
• Number of days in ICU (length of stay) up to Day 90  
• Number of days alive outside of hospital up to Day 28  
• Number of days alive outside of hospital up to Day 90  
• Pharmacokinetics in the study population at 100  mg QD  
Exploratory Endpoints:  
• See Section  3.2.3   
Subject Population  
• ≥18 years with  reverse transcriptase polymerase chain reaction  (RT-PCR ) confirmed infection 
with severe acute respiratory syndrome coronavirus 2 ( SARS -CoV -2)  
• COVID -19 pneumonia (documented radiographically) requiring hospitalization ; oxygen 
saturation level <94% on room air or subject requires supplemental oxygen.  
Refer to Section  5 for complete eligibility details.  
Investigational Product (IP)  Description:  
Investigational Product (IP)  is STI-5656 ( Abivertinib  maleate )  
Planned Sample Size  
Approximately 80 subjects will be enrolled  in this study, 40 will be randomized to each of two 
treatment  arms.   
Treatment  Arms  
All subjects will receive current standard of care (SOC) treatments.   
In this setting, subjects will receive one of two treatments  up to Day 14 or until hospital discha rge (if 
sooner) : 
Arm 1:  STI-5656  (100 mg QD starting dose)    
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 13 of 49 Arm 2:  Placebo QD  
Duration of Study  
For subjects, the total duration of the study will be up to 9 4 days (up to 4 days for the screening period 
plus up to 14 days for treatment and up to 90 days from randomization  for follow -up).   
The length of the study will be approximately 7 months ( 4 months for enrollment plus up to 90 days 
study duration).  
Study Design  
This is  a Phase 2, randomized , double blind, placebo -controlled , 2-arm multicenter study to assess the 
safety and efficacy of STI-5656  (capsule administered orally) in the setting of current standard of care 
(SOC ) in subjects with RT -PCR confirmed SARS -CoV -2 (COVID -19) infection and pneumonia 
(documented radiographically) requiring hospitalization .  Subjects must have oxygen saturation  levels  
< 94% on room air or subject requires supplemental oxygen.  
Eighty (80) subjects meeting eligibility criteria will receive SOC treatment and will be randomized at a 
1:1 ratio to one of two treatment arms  
• Arm 1:  STI-5656   
• Arm 2:  Placebo   
The starting dose of STI-5656  is 100 mg PO QD administered up to 14 days or until hospital discharge  
whichever is  sooner.  Placebo follows the same schedule.  
Subjects who discontinue at any time after randomization will not be replaced.  There is no treatment 
crossover in this study.  
Once subjects provide informed consent, they wi ll have screening assessments performed (up to a 7-
day screening window).  Study Day 1 is the day of randomization.  Subjects randomized should receive 
their first dose of STI-5656  or placebo  on the day they are randomized  (Day 1) .    
Subjects will be assessed daily while hospitalized.  Subjects in both arms are assessed for adverse 
events and toxicities  and all a dverse events should be reported regardless of treatment arm assignment 
or causality.   
PK samples will be collected from the first 20 subject s enrolled in this trial.  For sampling time points 
please refer to the schedule of a ssessments . 
Subjects will have an outpatient visit on Day 28 (for various study procedures) and a telephonic contact 
on Day 60  to collect any additional AEs and follow -up for unresolved AEs  to resolution or to 
establishment of a new baseline.   
SOC  treatments will be collected in the electronic case report form (e -CRF) until hospital discharge.  
Continued outpatient treatment (concomitant medications) will be collected until Day 28. Any 
investigational medication received will be collected until Day 90.   
Note:  Investigational medicines other than STI -5656 are prohibited up to Day 28 or hospital discharge.  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 14 of 49 Discharged subjects will be contacted at Day 60 and Day 90 to collect survival , any experimental 
treatments and  additional hospitalization information  since the study hospital discharge .   
Subjects should be encouraged to remain in the study even if S tudy Drug  is discontinued (for any 
reason).   
Statistical Design  
An evaluable sample size of 40 subjects per group (treatment arm) will provide 80% power 
(alpha=0.05, 2 -sided) to detect a difference between groups in the number of subjects alive and free of 
respiratory failure at Day 28. This assumes that 95.7% of subje cts who received STI-5656  plus SOC  
(group 1) and 70% of subjects who received only SOC  (group 2) will be alive and free of respiratory 
failure at Day 28.  This represents a treatment effect difference of approximately 26%.   
All tests of significance will be assessed at alpha level=0.05, 2 -sided.  
Figure  1: Study Design  
 
Schedule of Assessments (SOA)  
See Table  1 for SOA  
Data Monitoring  Committee  
An independent data monitoring committee (DMC)  will be established  under a charter for the trial  and 
tasked  to evaluate data from the study to ensure the ong oing safety of the study subjects and make 
recommendations to the Sponsor concerning safety and trial conduct.  A blinded independent 
statistician will be used to facilitate DMC support.  This statistician will have no role in the statistical 
assessments c onducted for the study at its conclusion.  Discussions with the independent statistician 
will be conducted during a closed session during the DMC deliberations.  Sponsor, CRO and study site 
personnel will only participate in the open session.  Unblinding o f a given subject to assess an AE 
stopping rule trigger will be handled in a way to keep the Sponsor, CRO (and staff) and study site 
personnel blinded.   
A futility analysis will be performed by an independent biostatistician after the first 40 subjects ar e 
enrolled.  
Additional details may be found in the Statistical Analysis Plan (SAP) for this study.  Screening
Day -7 to Day -1Randomization
1:1
40 subjects per 
Treatment ArmTreatment Arm 1
STI-5656 + SOC
STI-5656 up to Day 14 or 
hospital discharge if earlier
or
Treatment Arm 2
Placebo + SOC
Placebo up to Day 14 or 
hospital discharge if earlierFollow -up 
visit Day 28 
and 
Telephonic 
contact on
Day 60 and 
Day 90
Sorrento Therapeutics, Inc.  
STI-5656  (Abivertinib Maleate)               Protocol STI -5656 -2001 
Confidential                     Page 15 of 49 
         12-Jun-2020 2. SCHEDULE OF ASSESSMENTS  (SOA)  
Table  1: Schedule of Assessments  
Assessments  Screening  
(Day -4 
to -1) Day 1  
(Dose 1)1 Daily until 
hospital 
discharge  Hospital 
discharge or 
Early Term 2 Outpatient visit :  
Day 28  Telephone 
Follow -up 
at Day 60 
and 90 
Informed Consent  X      
Assess eligibility  X X     
Demographics3 X      
RT-PCR assay for SARS -CoV -24 X      
Medical history (including COVID -19 history)  X      
Concomitant medications  X X X X X  
Physical exam, including weight; height5 X   X X  
Vital signs6 X X X X X  
12-lead ECG (performed locally)7 X X     
Pregnancy test for FCBP only8 X X  X X  
Urinalysis9 X X X  X  
Blood for hematology , coagulation and  
chemistry10 X X X X X  
Blood for  CRP  , serum ferriti n, VEGF -A and 
cytokines11 
Day 3, 5, 7, 10, 14 and 28 only  X X X X X  
Respiratory Status12 X X X X   
Adverse Events13 X X X X X  
Assess clinical status14 X X X X   
IRT entry  (at screening, randomization, then 
early termination or study completion  X X  X  X 
Study Drug administration (QD p.o.)   X X15    
Sorrento Therapeutics, Inc.  
STI-5656  (Abivertinib Maleate)               Protocol STI -5656 -2001 
Confidential                     Page 16 of 49 
         12-Jun-2020 Assessments  Screening  
(Day -4 
to -1) Day 1  
(Dose 1)1 Daily until 
hospital 
discharge  Hospital 
discharge or 
Early Term 2 Outpatient visit :  
Day 28  Telephone 
Follow -up 
at Day 60 
and 90 
Sampling for pharmacokinetics16 X16 X16 X16    
Survival and additional experimental meds/ 
hospitalization/ICU status      X X 
Abbreviations: AEs: adverse events;  ALC: Absolute lymphocyte count; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CRP: C -reactive 
protein;  BUN: blood urea nitrogen; CMP: complete metabolic panel; COVID -19: Coronavirus Disease 2019; D: day; ECG: electrocardiogram; ECMO: 
extracorporeal membrane oxygenation ; ET: Early Termination; F: Fahrenheit; FCBP: female of childbearing potential; FiO 2: Fraction of inspired oxygen; IRT: 
Interactive Response Technology; IL: Interleukin; IFN γ: interferon gamma; QD: once daily; PaO 2: partial pressure of oxygen in arterial blood;  p.o.: by mouth; 
RBC: red blood cells; rbc/hpf: red blood cells per high power field; RRT: rapid response team; RT- PCR: Reverse transcription polymerase chain reaction ; 
TNF: tumor necrosis factor alpha; WBC : white blood cells  
 
1 All assessments on Day 1 are to be performed prior to first dose of STI -5656.  Day 1 laboratory results do not need to be available prior to randomization (and 
first dose o f STI -5656 if assigned to that arm) if lab results are available from the previous 24 hours  
2 If the subject  wishes to discontinue from the study prior to Day 28 or hospital discharge , every effort should be made to perform an Early Termination (ET) 
Visit within 7 days after the decision to discontinue the study.  
3 Demographics includes age, sex, race, ethnicity, date of birth.  
4 SARS -CoV -24 positive RT -PCR test results received more than 7 days prior to planned randomization may be used to confirm eligibility if the site is u nable to 
obtain a repeat sample and confirm re sults prior to planned randomization day and if the subject has progressive disease consistent with COVID -19. 
5 Height at screening only  
6 Vital signs include body temperature (F), respiratory rate, radial pulse rate, systolic and diastolic blood pressure, and oxy gen saturation (pulse ox imetry ).  Pulse 
and blood pressure should be t aken with subject in at least in a semi -recumbent position.  It is preferred to collect vital signs  approximately mid -afternoon each 
day. Vital signs may be obtained at additional times  as deemed necessary by the Investigator . 
7 ECG to be performed at Screening , between 2 and 4 hours after study drug dosing, and as clinically indicated.  
8 Females of childbearing potential must have a neg ative pregnancy test at screening and within 24 hours before randomization (Day 1) unless the previous 
negative pregnancy test was within 72 hours of Day 1.  Urine pregnancy test is acceptable.   The test should be repeated at the time of  the Day 28 visit . 
9 Urinalysis performed locally. Urinalysis includes protein, glucose, and blood (microscopic) – red blood cells per high power field (rbc/hpf).  
10 Laboratory tests performed locally.   
 Hematology : Hemoglobin, hematocrit, red blood cell (RBC) count, RBC indices, mean corpuscular hemoglobin, mean corpuscular hemoglobin 
concentration, platelet count (or estimate), and white blood cell coun t including differential.  
 Coagulation: INR, PTT.  
Chemistry:  performed locally. 14 -analyte complete metabolic panel (CMP) :  Albumin, alkaline phosphatase  (ALP) , alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), bicarbonate, total bilirubi n (TBIL) , blood urea nitrogen (BUN), calcium, chloride, creatinine, glucose, potassium, sodium, 
total protein , D-dimer, fibrinogen.  
11 Cytokines include TNF , IFNγ, IL-6, IL -1β, IL-7, IL-8, IL-10, IL -12, IL -17, IL -18, IP 10, VEGF -A  
Sorrento Therapeutics, Inc.  
STI-5656  (Abivertinib Maleate)               Protocol STI -5656 -2001 
Confidential                     Page 17 of 49 
         12-Jun-2020 12 Record FiO 2 (and PaO 2) at the time of arterial blood gas sampling.  If PaO2 is not available, use SPO 2. Other respiratory status data to collect incl udes oxygen 
supplementation status:  mechanical ventilation, face mask, nasal cannula or room air.  Radiographic findings will also be co llected.  
13 AEs will be collected from the time of informe d consent to Day 60 .  Any ongoing AEs at Day 28 will be followed until resolution or stabilization.  
14 An 8 -category ordinal scale of patient health status ranges:  0=no clinical or virological e vidence of infection; 1=no limitation of activities; 2=limitation of 
activities; 3=hospitalized, no oxygen therapy; 4=oxygen by mask or nasal prongs; 5=non -invasive ventilation or high -flow oxygen; 6=intubation and 
mechanical ventilation; 7=ventilation + a dditional organ support – pressors, rapid response team (RRT), extracorporeal membrane oxygenation (ECMO); 
8=death.   See Section  14.2 for form.  
15 STI-5656 or placebo administration up to Day 14 or hospital discharge, whichever is sooner for subjects in Treatment Arm 1.  Study drug  capsules should be 
taken orally with 200 -250 mL of water f ollowing at least 2 hours of fasting.   
16Samples will be collected from the first 20 subjects enrolled. Sampling timepoints are as follows: Day 1 (predose) and at 0.5, 1, 2, 4, 8, 12, postdose on dosing 
days 1 and 8.  
 
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 18 of 49
  3. STUDY  OBJECTIVES AND ENDPOINTS  
3.1. Objectives  
3.1.1.  Primary Objective  
To assess the efficacy of STI-5656  in subjects with severe COVID -19 
3.1.2.  Secondary Objective s 
To assess the safety and tolerability of STI-5656  in subjects with severe COVID -19 
To assess pharmacokinetics in the study population.  
3.2. Endpoints  
3.2.1.  Primary Endpoint  
• Proportion of s ubject s alive and free of respiratory failure at Day 28 
Respiratory failure, is defined based on resource utilization of any of the following 
modalities:  
− Noninvasive positive pressure ventilation or continuous positive airway pressure  
− Endotracheal intubation and mechanical ventilation  
− Oxygen delivered by high -flow nasal cannula (heated, humidified, oxygen 
delivered via reinforced n asal cannula at flow rates >20 L/min with fraction of 
delivered oxygen ≥0.5)  
− Extracorporeal membrane oxygenation  
3.2.2.  Secondary Endpoints  
• Types, frequencies, and severities of AEs and the relationships of AEs to IP; includes 
serious adverse events SAEs  
• Proporti on of subjects alive and free of respiratory failure at Day 60 
• Change in clinical status (on a 0 -8-point ordinal scale2) of subject at Day 7, Day 14, 
and Day 28  
• Proportion of subjects alive and discharged from ICU at Days 14 and 28  
 
2 8-category ordinal scale of patient health status ranges:  0=no clinical or virological evidence of infection; 1=no 
limitation of activities; 2=limitation of activities; 3=hospita lized, no oxygen therapy; 4=oxygen by mask or nasal 
prongs; 5=non -invasive ventilation or high -flow oxygen; 6=intubation and mechanical ventilation; 7=ventilation + 
additional organ support – pressors, rapid response team (RRT), extracorporeal membrane oxy genation (ECMO); 
8=death.  
 
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 19 of 49
  • Time from randomization  to first occurrence of respiratory failure or death on study 
due to any cause up to Day 28  
• Percent change from baseline in CRP at Days 3, 5, 7, 10, 14, 28  
• Relative change from baseline in oxygenation index (PaO2/FiO2) up to Day 5  
• All-cause mortality at Day 60 and Day 90  
• Number of days alive and free of respiratory failure at Day 28  
• Number of days with respiratory failure up to Day 28  
• Number of days hospitalized up to Day 28  
• Number of days in ICU (length of stay) up to Day 90  
• Number of days alive outside of hospital up to Day 28  
• Number of days alive outside of hospital up to Day 90  
• To assess the pharmacokinetic profile in the study population  
3.2.3.  Exploratory Endpoints  
• Change from baseline in absolute lymphocyte counts at Days 3, 5,  7, 10, 14, 28  
• Change from baseline in ferritin at Days 3, 5, 7, 10, 14, 28  
• Change from baseline in VEGF -A at Days 3, 5, 7, 10, 14, 28  
• Change from baseline for inflammatory cytokines (IL -6, TNF -, IFNγ, IL1β, IL -7, 
IL-8, IL-10, IL -12, IL -17, IL -18, IP-10) at Days 3, 5, 7, 10, and 28  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 20 of 49
  4. INVESTIGATIONAL PLAN  
4.1. Overall Study Design  
This is a Phase 2, randomized , double -blind, placebo -controlled , 2-arm multicenter study to 
assess the safety and efficacy of oral STI-5656 ( or placebo ) in the setting of current  SOC  in 
subjects with RT -PCR confirmed SARS -CoV -2 infection and COVID -19 pneumonia 
(documented radiographically) requiring hospitalization.  Subjects must have oxygen saturation 
levels <94% on room air or subject requires supplemental oxygen.  
Eighty (80) subjects meeting eligibility criteria will be randomized at a 1:1 ratio to one of two 
treatment arms in addition to SOC treatments:  
• Arm 1:  STI-5656  
• Arm 2:  Placebo  
The STI-5656  dose is 100 mg p.o. QD administered up to 14 days or until hospital discharge if 
sooner.   
SOC treatments will be collected in the electronic case report form (e -CRF ). 
Subjects who discontinue at any time after randomi zation will not be replaced.  There is no 
treatment crossover in this study.  
Once subjects  provide informed consent, they will have screening assessments performed (up to 
4-day screening window).  Study Day 1 is the day of randomization.  Randomized Subjec ts 
should receive their first dose of Study Drug  on Day 1 .    
Subjects will be assessed daily while hospitalized.  Subjects in both arms are assessed for 
adverse events (AEs) and toxicities and all AEs should be reported regardless of treatment arm 
assignment or causality.  Subjects will be contacted on Day 28 to collect any additional AEs and 
follow -up for unresolved AEs,  
SOC treatments will be collected in the electronic case report form (e -CRF) until  hospital 
discharge.  Continued outpatient treatment (concomitant medications) will be collected until Day 
28. Any investigational medication received will be collected until Day 90.  Note:  
Investigational medicines other than STI -5656 are prohibited up t o Day 28 or hospital discharge.  
Discharged subjects will be contacted at Day 60 and 90 to ensure survival  and collect  any 
experimental treatments and additional hospitalization information since the study hospital 
discharge.  Subjects on Treatment Arm 1 ( STI-5656 ) should be encouraged to remain in the 
study even if Study Drug  is discontinued (for any reason).   
An independent  data monitoring  committee (DMC) is established to evaluate the safety data 
from the study to ensure the ongoing safety of the study s ubjects and make recommendations to 
the Sponsor concerning safety and trial conduct  (please refer to the DMC charter for details).   A 
blinded independent statistician will be used to facilitate DMC support.  This statistician will 
have no role in the stat istical assessments conducted for the study at its conclusion.  Discussions 
with the independent statistician will be conducted during a closed session during the DMC 
deliberations.  Sponsor, CRO and study site personnel will only participate in the open s ession.  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 21 of 49
  Unblinding of a given subject to assess an AE stopping rule trigger will be handled in a way to 
keep the Sponsor, CRO (and staff) and study site personnel blinded.  
The study visit schedule and assessments are detailed in Table  1 Schedule of Assessment (SOA).    
For subjects, the total duration of the study will be up to 9 4 days (up to 4 days for the screening 
period plus up to 14 days for treatment and up to 90 days from randomization  for follow -up).   
The length of the study will be approximately 7 months ( 4 months  for enrollment plus up to 90 
days study duration).  
4.2. End of Trial Definiti on 
The End of Trial is defined as either the date of receipt of the last data point from the last subject  
that is required for primary, secondary and/or exploratory analysis, as prespecified in the 
protocol, whichever is the  later date.  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 22 of 49
  5. SELECTION AND WITHD RAWAL OF SUBJECT S 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
Subject s who are randomized but discontinue  prior to the end of the study will not be repl aced.   
5.1. Subject Inclusion Criteria  
Subject s are eligible to be included in the study only if all the following criteria apply:  
1. Confirmed infection with SARS -CoV -2 per World Health Organization (WHO) criteria 
(including positive RT -PCR nucleic acid test of any specimen [eg, respiratory, blood, 
urine, stool, or other bodily fluid]) within 7 days of randomization .  Positive RT -PCR test 
results more than 7 days prior to randomization is allowed if the site is unable to obtain a 
repeat sample and if the subje ct has progressive disease consistent with COVID -19. 
2. COVID -19 pneumonia (documented radiographically) requiring hospitalization and 
oxygen saturation <94% on room air or  subject  requires supplemental oxygen . 
3. Age ≥18 years  at the time of signing the informe d consent form  
4. Subject or family member/caregiver must have provided written informed consent which 
includes signing the institutional review board approved consent form prior to 
participating in any study related activity.  However, if obtaining written i nformed 
consent is not possible, other procedures as provided in the March 27th, 2020 FDA 
Guidance on Conduct of Clinical Trials of Medical Products during COVID -19 
Pandemic, Question 10, may be used.  
5. Able to swallow capsules  
6. Willing to follow contraceptio n guidelines   
If a female , be sterile (surgically or biologically)* or at least one year post -menopausal**, or 
have a monogamous partner who is surgically sterile, or have a same sex partner, or if in a 
heterosexual relationship, must agree to do the foll owing for at least 1 month after receiving 
IP: 
• Practice abstinence  
• Use at least 1 of the following medically acceptable methods of birth control:  
− Hormonal methods such as oral, implantable, injectable, vaginal ring, or 
transdermal contraceptives (must have started a minimum of 1 full cycle, based 
on the subject’s usual menstrual cycle period, before IP dose 
− Intrauterine device  
− Double -barrier method (condoms, sponge, or diaphragm with spermicidal jellies 
or cream).  
*Defined as having had a hysterectomy and/or bilateral oophorectomy, bilateral 
salpingectomy or bilateral tubal ligation/occlusion at least 6 weeks prior to screening; 
or having a congenita l or acquired condition that prevents childbearing  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 23 of 49
  **Defined as at least 12 months with no menses without an alternative medical cause) 
[can be confirmed with follicle stimulating hormone level (FSH) in the post -
menopausal range (FSH levels ≥40 milli inter national units/mL ( mIU/mL ) at 
Screening) if the subject is not on hormonal replacement therapy]  
If a male  of reproductive potential*, unless he has a same sex partner, must agree to do the 
following for at least 1 month  after receiving IP 
• practice abstinence from heterosexual activity, or  
• use (or have their partner use) acceptable contraception (see criterio n above) during 
heterosexual activity  
*Defined as  having azoospermia, whether due to having had a vasectomy or due to an 
underlying medical  condition.  
5.2. Subject Exclusion Criteria  
Subject s are excluded from the study if any of the following criteria apply:  
1. Known cardio -pulmonary  resuscitation within 14 days of randomization  
2. Pregnant or breast feeding  
3. Suspected uncontrolled active bacterial, fungal, viral, or other infection (besides infection 
with SARS -CoV -2) 
4. Alanine aminotransferase (ALT)  ≥ 3x upper limit of normal ( ULN ) and total bilirubin 
> 2x ULN  
5. QTcF prolongation >480 m illiseconds  
6. Uncontrolled or untreated symptomatic arrhythmias, myocardial infarction within the last 
6 weeks, or congestive heart failure (NYHA Grade 3 or 4). Exception: Subjects  with 
controlled, asymptomatic atrial fibrillation during screening are allowed to enroll  
7. Treatment with a strong cytochrome P450 (CYP3A 4 inhibitor (within 14 days before first 
dose of study drug) or inducer (within 7 days before first dose of study drug).  
8. Received anti -rejection or immunomodulatory drugs (eg, anti -cytokines, B TK inhibitors, 
JAK inhibitors, PI3K inhibitors) within 30 days before randomization on study  
9. Concurrent participation in another clinical trial involving therapeutic interventions 
(observational study participation is acceptable).  
10. Any condition that confound s the ability to interpret data from the study.  
11. Relevant renal impairment (eGFR <60ml/min)  
12. Any significant medical condition, laboratory abnormality or psychiatric illness that 
would interfere or prevent the subject from participating in the study.  
5.3. Screen Failures  
Screen failures are defined as subject s who consent to participate in the clinical  study but are not 
subsequently entered in the study . A minimal set of screen failure information is required to 
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 24 of 49
  ensure transparent reporting of  screen failure subje cts to meet the Consolidated Standards of 
Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory 
authorities. Minimal information includes demograph ics, screen failure details, eligibility 
criteria, and any  SAE.  
Indivi duals who meet all the screening criteria but were not selected for cohort may be re -
screened to participate in a subsequent c ohort.   Screening laboratory tests and/or vital signs may 
be repeated once  if, in the opinion of the Investigator, the out -of-range values are thought to be 
spurious and not indicative of an underlying disease or abnormality.  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 25 of 49
  6. TREATMENT OF PARTICPANTS  
6.1. Description of Investigational Product  
Study treatment  will be either STI-5656  (Investigational Product, or I P) or placebo . 
6.2. Investigational Product  Administration  
Two STI-5656  or matching placebo capsules p.o. QD (two 50-mg capsules) administered up to 
14 days or until hospital discharge if sooner . 
Study drug  capsules should be taken orally with 200 -250 mL of water following at least 2 hours 
of fasting.    
If vomiting occurs within 30  minutes after a patient takes the dose and the patients can tolerate 
the medication, the vomited dose should be made up.  
If the subject is unable to swallow, the capsule contents may be flushed down a nasogastric or 
feeding tube with water.  
6.3. Stopping Rule Triggers  
Study drug dose should be paused per the guidelines in Table  2 (using the Common Terminology 
Criteria for Adverse Events, Version 5.0 [CTCAE]  for severity grading ). 
Table  2: Stopping Rule Triggers  
If any of the follo wing  possibly related AEs  occur : 
• ≥ Grade 3 (G3) non -hematologic toxicities  
• ≥ G3 alanine aminotransferase (ALT) elevation   OR ≥ any ALT and 
total bilirubin elevation in combination which meet Hy’s Law 
criteria  [i.e., any ≥ G3 hepatic impairment]  
• G3 thrombocytopenia with bleeding  
• G4 thrombocytopenia  
• G4 neutropenia  
• G3 neutropenia or thrombocytopenia in ˃ 3 subjects   
• ≥ G3 renal im pairment including acute kidney injury requiring 
hemodialysis  
• Any SUSAR (suspected unexpected serious adverse reaction)  At the first occurrence of 
any of the stopping rule 
triggers, d iscontinue 
Study Drug for the 
affected subject and pause 
further enrollme nt until 
DMC deliberations have 
been completed and a 
DMC decision t hat 
enrollment may be 
restarted  has been 
rendered.  
A DMC teleconference will be arranged within 5 business  days of the stopping rule trigger.  This 
should  provide sufficient time for the C RO to prepare a blinded summary of the AE and the 
independent statistician to arrange to be unblinded to assist the DMC in its deliberations.   
Additionally, the DMC will be provided with tabular safety summaries at 25%, 50% and 75% 
enrollment for ongoing s urveillance.   
6.4. Dosing of Subjects Unable to Take Test Article PO  
Subjects unable to take the capsules PO, for example after intubation may receive the drug or 
placebo via feeding tube. The formulation is blended powder filled in capsule  allowing for 
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 26 of 49
  opening the capsules and dosing the content as is  with water to flush t he feeding tube .  If this is 
not feasible, dosing should be discontinued.  
6.5. Investigational Product  Compliance  
Subject s receive IP only while hospitalized  and it is administered at the site; therefore, the site 
will monitor IP compliance.  
6.6. Overdose  
Any dose over the protocol -specified daily dose of STI-5656  will be considered an overdose. 
The Sponsor does not recommend specific treatment for an overdose . 
In the event of an overdose, the I nvestigator should:  
• Contact the Medical Monitor immediately.  
• Closel y monitor the subject  for any AE/SAE  for at least 24 hours.  
• Document the quantity of the excess dose.  
6.7. Randomization and Blinding  
Screening, randomization  to one of two treatment arms (1:1 ratio) , as well as study completion or 
study discontinuation will be registered by the site using an I RT system .  
6.8. Emergency Unblinding  
Emergency unblinding may be requested by the Investigator at any time if needed to properly 
assess the patient .  The request should be submitted to the CRO and Sponso r’s medical monitor.  
6.9. Concomitant Medications  
Any medication  (including over the counter  or prescription medicines, vitamins, and/or herbal 
supplements), vaccine or transfusion  that the subject  received within 28 days prior to the 
Screening Visit and during  the study  up to hospital discharge  must be recorded along with:  
• Reason for use  
• Dates of administration including start and end dates  
• Dosage information including dose and frequency  
The Medical Monitor should be contacted if there are any questions regarding concomitant or 
prior therapy.  
6.9.1.  Prohibited Concomitant Medications  
The following medications are prohibited up to Day 28 or hospital discharge :  
Anti-cytokines, other BTK inhibitors or other tyrosine kinase inhibitors (e.g. JAK or PI3K  
inhibitors  as well as any immunosuppressive drugs (except steroids), such as anti -IL6 or anti -
TNF therapy.  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 27 of 49
  7. IP MATERIALS AND MANAGEMENT  
7.1. Investigational Product  
IP  STI-5656 (Abivertinib maleate)  Placebo  
Dose 
Formulation  Capsule for oral administration  Capsule for oral administration  
Unit Dose 
Strength(s)  50 mg  n/a 
Dose to be 
administered 
to subjects  200 mg QD (4 capsules once daily)  4 capsules once daily  
Route of 
Administration  p.o. (by mouth)  p.o. (by mouth)  
Use Experimental   
Manufacturer  Shanghai Syn -The-All Pharmaceutical 
Co. Ltd. (“STA”), a wholly owned 
subsidiary of WuXi AppTec Co.  Shanghai Syn -The-All Pharmaceutical 
Co. Ltd. (“STA”), a wholly owned 
subsidiary of WuXi AppTec Co.  
Sourcing  Provided centrally b y Sorrento 
Therapeutics, Inc. or a Sorrento 
representative  Provided centrally by Sorrento 
Therapeutics, Inc. or a Sorrento 
representative  
Packaging and 
Labeling  40 Capsules packaged inside an HDPE 
bottle and closed with a polypropylene 
cap. 40 Capsules pa ckaged inside an HDPE 
bottle and closed with a polypropylene 
cap. 
7.2. IP Packaging and Labeling  
STI-5656  will be distributed  to the investigational site’s pharmacy. The site pharmacist will 
dispense STI-5656  to subjects in Treatment Arm 1.  
The labels on the study drug bottles will include the following information:  
• Protocol Number  
• Lot Number  
• Name of product and strength of each capsule  
• Storage conditions  
• Sponsor’s name and address  
• The statement: “Caution: New drug -limited by Federal Law to Investigationa l Use. 
Keep out of reach of children.”  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 28 of 49
  7.3. IP Storage  
The shelf life of  STI-5656  is at least 3 years when stored at room temperature (approximately 20º 
to 25°C [68º to 77°F]).  
7.4. IP Accountability  
The Principal Investigator (or designee) is responsible for accountability of all used and unused 
IP at the site.  
The IP provided by the Sponsor  must be made available for inspection by the Sponsor or its 
representatives and regulatory agency inspectors up on request.  
7.5. IP Handling and Disposal  
The Investigator must keep an accurate accounting of the number of bottles and capsules of STI-
5656  delivered to the site, administered to subject s, and returned to the Sponsor/Sponsor 
representative or other dispositio n during and at the completion of the study.   
The IP must be dispensed to subject s only by an appropriately qualified person.  The IP is to be 
used in accordance with the protocol by subject s who are under the direct supervision of the 
Investigator.  Inve stigators should maintain records that document adequately that the subject s 
were provided the doses specified by the protocol and reconcile all IP received at the site before 
final disposition.   
All IP, including unused, partially used, and empty contain ers, should be disposed of in 
accordance with federal, state and local regulations and the institutional standard operating 
procedures (SOPs) or returned to the Sponsor/Sponsor representative as directed if destruction at 
the site is not possible.  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 29 of 49
  8. STUDY PR OCEDURES  
Study procedures will be performed as described in the Schedule of Assessment Table  1.  
Additional unscheduled visit/assessments may be performed at any time if clinically indicated 
and will be captured in the eCRFs if performed.  
Protocol waivers or exemptions are not allowed, with the exception of immediate safety 
concerns . Such concerns  should be discussed with the Sponsor immediately upon occurrence or 
awareness to determine if the subject  should continue or discontinue the IP (subjects in 
Treatment Arm 1) . Adherence to the s tudy design requirements, including those specified in the 
Schedule of Assessments, is essential and required for study conduct.  
All screening evaluations must be completed and reviewed to confirm that potential subjects 
meet all eligibility criteria. The  Investigator will maintain a screening log to record details of all 
subjects screened and to confirm eligibility or record reasons for screening failure, as applicable.  
A subject may be re -screened once for the study if the defined screening period has b een 
exceeded and the subject has not been randomized in the study.  
8.1. Description of Procedures  
8.1.1.  Informed Consent  
All subjects will review and sign an IRB -approved Informed Consent Form prior to performing 
any procedures specifically for this study.  
8.1.2.  RT-PCR assay for SARS -CoV -2 
If RT -PCR confirmation of SARS -CoV -2 is not within 7 days prior to planned randomization, 
then p ositive RT -PCR test results more than 7 days prior to randomization is allowed  to confirm 
eligib ility if the site is unable to obtai n a repeat sample and if the subject has progressive disease 
consistent with COVID -19. 
8.1.3.  Collection of Demographics, Medical History, Prior and Concomitant 
Medications  
Demographics include age, sex, race, ethnicity, date of birth.  
Current (active) medical co nditions and relevant (non -active) medical history .  Details of 
COVID -19 history should include COVID -19-related symptoms, time of onset of symptoms, 
date of first positive COVID -19 test result  
Concomitant medications and prior medications taken within 28  days of informed consent  
8.1.4.  Vital Signs  
Vital signs include body temperature (F), respiratory rate, radial pulse rate, systolic and diastolic 
blood pressure, and oxygen saturation (pulse oximetry).  Pulse and blood pressure should be 
taken with subject in at  least in a semi -recumbent position.   
It is preferred to collect vital signs at approximately mid-afternoon each day . Vital signs may be 
obtained at additional times as deemed necessary by the Investigator.  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 30 of 49
  8.1.5.  Physical Exam  
A physical exam should be performe d at Screening and at hospital discharge or Early 
Termination Visit, whichever is later.  Height (at screening) and weight (screening and 
discharge) should be recorded also.  
8.1.6.  12-lead Electrocardiogram (ECG)  
A 12 -lead ECG is to be performed during Screening , between  2 and 4 hours after study drug 
dosing  and at any time a subject complains of anything suggestive of a cardiac abnormality.    
8.1.7.  Clinical laboratory tests  
Serum chemistry, hematology , coagulation,  urinalysis and urine pregnancy tests are to be 
performed locally.  
8.1.7.1.  Serum Chemistry  
Albumin, alkaline phosphatase  (ALP) , alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), bicarbonate, total bilirubin  (TBIL) , blood urea nitrogen (BUN), 
calcium, chloride, creatinine, glucose, potassium, sodium, total protein , D-dimer, fibrinogen.  
8.1.7.2.  Hematology  
Hemoglobin, hematocrit, red blood cell (RBC) count, RBC indices, mean corpuscular 
hemoglobin, mean corpuscular hemoglobin concentration, platelet count (or estimate), and white 
blood cell count includi ng differential.  
8.1.7.3.  Coagulation  
International normalized ratio (INR), PTT.  
8.1.7.4.  C-reactive protein, serum ferritin , absolute lymphocyte count and cytokines  
Blood should be collected for measuring C -reactive protein ( CRP ), serum ferritin , VEGF -A, and 
cytokines (IL-6, TNF -, IFNγ, IL1β, IL -7,IL-8,  IL-10, IL -12, IL -17, IL -18, IP10) should be 
measured on Days 3, 5, 7, 10, 14 and 28.  
8.1.7.5.  Urinalysis  
Urinalysis to be performed locally. Urinalysis includes protein, glucose, and blood (microscopic) 
– red blood cells per high  power field (rbc/hpf).  
8.1.7.6.  Urine Pregnancy Test  
Urine pregnancy tests (B -HCG) will be performed (locally) for women of childbearing potential.  
FSH tests may be performed to confirm a woman is of non -childbearing potential if the subject  is 
not on hormonal replacement therapy or not surgically sterile (refer to eligibility criteria for 
details).  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 31 of 49
  8.1.8.  Respiratory Status  
Record FiO2 (and PaO2) at the time of arterial blood gas sampling.  If PaO2 is not available, use 
SPO2. Other respiratory stat us data to collect includes oxygen supplementation status:  
mechanical ventilation, face mask, nasal cannula or room air.  Radiographic findings will also be 
collected.  
8.1.9.  Clinical status using 8 -category ordinal scale of patient health status  
An 8 -category o rdinal scale of patient health status ranges will be used to collect subject clinical 
status where  
0 = no clinical or virological evidence of infection;  
1 = no limitation of activities;  
2 = limitation of activities;  
3 = hospitalized, no oxygen therapy;   
4 = oxygen by mask or nasal prongs;  
5 = non -invasive ventilation or high -flow oxygen;  
6 = intubation and mechanical ventilation;  
7 = ventilation + additional organ support – pressors, rapid response team (RRT), 
extracorporeal membrane oxygenation (ECM O);  
8 = death.  
See Section  14.2 for form.  
8.1.10.  IRT Registration, Randomization and Study Discontinuation or Completion.   
Subjects will be registered in IRT after signing informed consent and will be randomized using 
the IRT on Day 1 to either Treatment Arm 1 ( STI-5656  plus SOC ) or Treatment Arm 2 ( placebo 
plus SOC ) using central integrated response technology (IRT).  Subject study discontinuation or 
study  completion should also be registered in the IRT.  
8.1.11.  Adverse Events  
Adverse events will be collected from the time of signing the ICF through Day 60. 
8.1.12.  Follow -up contact  
The subject will be seen on Day 28 to collect laboratory samples, report on any additional AEs 
and on the status of unresolved AEs.  The subject will also be contacted at Day  60 and  90 to 
document survival (or collect date of death from family or subject’s physician).  In addition,  any 
experimental medication,  duration of any additional hospital  or ICU admissions after the first 
“post -randomization” discharge will also be collected.  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 32 of 49
  8.2. Procedures by Study Day  
8.2.1.  Screening  
• Informed Consent  
• Registration of screening in IRT  
• RT-PCR assay for SARS -CoV -2 (if needed , see details in Section  8.1.2 ) 
• Collection of Demographics, Medical History, Prior and Concomitant Medications  
• Vital Signs  
• Physical Exam  
• 12-lead ECG  
• Clinical laboratory tests per Section 8.1.7  
• Respiratory Status  
• Clinical status using 8 -category ordinal scale of patient health status  
• Assess eligibility  
8.2.2.  Study Day 1  
• Vital Sign s 
• Clinical laboratory tests per Section 8.1.7  
• Respiratory Status  
• Collect adverse events since screening  
• Collect con meds  
• Clinical status using 8 -categ ory ordinal scale of patient health status  
• Randomization in IRT  
• Dispense STI -5656 or placebo capsules to subjects  which  should be taken orally with 
200-250 mL of water following at least 2 hours of fasting.    
• 12-lead ECG to be performed between 2 and 4 hours post study drug dosing  
8.2.3.  Daily until Hospital Discharge  
• Vital Signs  
• Clinical laboratory tests per Section 8.1.7 .  Note that the urine pregnancy te st is 
performed only at Screening, prior to randomization on Day 1 and at hospital 
discharge.  
• Respiratory Status  
• Collect adverse events  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 33 of 49
  • Collect con meds  
• Clinical status using 8 -category ordinal scale of patient health status  
• Dispense S tudy Drug  to subjects  which should be taken orally with 200 -250 mL of 
water following at least 2 hours of fasting.    
8.2.4.  Hospital Discharge or Early Termination from Study  
• Physical Exam  
• Vital Signs  
• Clinical laboratory tests per Section 8.1.7  
• Respiratory Status  
• Collect adverse events  
• Collect con meds  
• Clinical status using 8 -category ordinal scale of patient health status  
• If early termination, register in IRT  
8.2.5.  Outpat ient Follow -up Day 28  
• Collect AEs, and update status on previously unresolved AE status  
• Clinical laboratory tests per Section 8.1.7  
• Collect survival, experimental medications since hospital discharge, any new 
hospitalizations/ ICU stays  
8.2.6.  Telephone Follow -up Day 60  
• Update status on previously unresolved AEs  
• Collect survival , experimental medications since hospital discharge, any new 
hospitalizations/ ICU stays  
8.2.7.  Telephone Follow -up Day 90  
• Update status on previously unresolved AEs  
• Collect survival, experimental medications since hospital discharge, any new 
hospitalizations/ I CU stays  
8.3. Blood Volumes collected  
Blood for hematology , coagulation  and chemistry should be standard of care  along with the 
addition of  D-dimer and fibrinogen to the chemistry assessments .  Blood collected for measuring 
CRP, serum ferritin and cytokines (IL -6, TNF -, IFNγ, IL1β, IL -7, IL -10, IL -12, IL -17, IL -18 is 
approximately 6.5 mL per time point.  Time points are Day 1 (baseline), Day 3, 7, 10, 14 and 28 
(or at hospital discharge).  The total blood volume collected for these measurements is 
approximately  60 mL per subject.  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 34 of 49
  9. STATISTICS  
9.1. Statistical Consideration s 
All tests of significance will be assessed at alpha level=0.05, 2 -sided. All analyses and data 
presentations will be generated using SAS version 9.4, or higher (Cary, NC).  
Subjects who are randomized to the study and discontinue before the end of the study will not be 
replaced.   Missing values will not be imputed. For success/failure endpoints, subjects who 
discontinue prior to the specified time point will be included in th e analysis as treatment failures 
and censored at the last day of follow -up for the time -to-event analysis. For all other endpoints, 
the mixed effect model repeat measurement (MMRM) analysis will be employed. The MMRM 
analysis only includes the available da ta. It has been demonstrated that the MMRM approach 
leads to estimators with comparatively small bias, and controls Type I error rates at a nominal 
level in the presence of missing completely at random (MCAR) or missing at random (MAR) 
and some possibility  of missing not at random (MNAR) data  (see 
https://pubmed.ncbi.nlm.nih.gov/19212876/ ). 
9.2. Sample Size Estimation  
An evaluable sample size of 40 subjects per group will provide 80% power (alpha=0.05, 2 -sided) 
to detect a difference between groups in the number of subjects alive and free of respiratory 
failure at Day 28. This assumes that 95.7% of subjects who received  STI-5656  plus SOC  and 
70% of subjects who received placebo plus SOC  only will be alive and free of respiratory failure 
at Day 28. This represents  a treatment effect difference of approximately 26%.   
9.3. Analysis Population  
The following analysis populations are planned:  
• Safety population: All randomized subject s 
• Full Analysis (FA) population: All randomized subjects  
• Per-protocol (PP) population: Subset of the Full Analysis Set and excludes subjects 
with major protocol violations, entry criteria violations or missing visits. The results 
of the Full Analysis Set will be considered primary.  
9.4. Data Analysis  
9.4.1.  Subject  Disposition  
The number and percentage of subjects included in each population, who completed the study, 
who discontinued study and reason for discontinua tion will be presented for each cohort and 
treatment.  
9.4.2.  Demographics and Baseline Characteristics  
Demographic and baseline characteristics will be presented for each population by Treatment 
arm. 
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 35 of 49
  9.4.3.  Primary Endpoints  
For the primary endpoint, the proportion of subject s alive and free of respiratory failure at Day 
28, the number and percentage of subjects w ill be presented by group. Possible differences 
between groups will be assessed using a generalized linear mixed model, assuming a binomial 
distribution and a logit link. The model will include group as a fixed effect.  Subjects who 
discontinue the study pr ior to Day 28 will be considered treatment failures.  
9.4.4.  Secondary Endpoints (Safety)  
AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA ) and will 
be summarized by System Organ Class (SOC) and Preferred Term for each group. The fi rst 
occurrence will be tabulated for an event that occurred more than once for a subject. 
Additionally, AEs will be tabulated by maximum severity and nearest relationship to IP. SAEs 
will be summarized similarly to AEs.  
For continuous safety endpoints, des criptive statistics (number of subjects, mean, standard 
deviation, minimum, median and maximum values) will be presented by group and study day. 
The changes from Day 1 to each subsequent day will be calculated for each subject and 
descriptive statistics wi ll be presented. Possible differences between groups will be assessed 
using a mixed effect model repeat measure ment  (MMRM)  analysis of covariance. The model 
will include the Day 1 value as a covariate, fixed effects of group, study day and group -by-study 
day interaction with subject as a random effect.  
Categorical safety endpoints will be summarized as the number and percentage of subjects per 
category for each group.  
Treatment -emergent adverse events (TEAE) will be defined as any AE occurring post first 
administration. Adverse events  will be presented for each cohort and treatment  by System Organ 
Class (SOC) and Preferred Term (PT) : 
• Treatment -emergent adverse events (TEAE) : defined as any AE occurring postdose 
administration  through 2 8 days following IP administration.  
• IP related TEAEs  
• SAEs  
• IP related SAEs  
• TEAEs (by grade and relationship to IP)  
• Laboratory abnormalities by toxicity grade  
9.4.5.  Secondary Endpoints (Efficacy)  
The proportion of subjects alive and discharged from the ICU at Day 14 and Day 28 and the 
proportion alive and free of respiratory failure at Day 60 and will be presented and analyzed as 
described for the primary efficacy endpoint.  Subjects who discontinue  from the study prior to 
each study day will be considered treatment failures.  
Clinical Status will be assessed using a generalized linear mixed model , assuming a multinomial 
distribution . The model will include the Day 1 value  as a covariate  with fixed ef fects of group, 
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 36 of 49
  study day and group -by-study day interaction and subject as a random effect.  If the group -by-
study day interaction is found to be statistically significant then comparisons between groups at 
Day 7, Day 14 and Day 28 will be obtained from th is model.  Additionally, stacked bar charts 
will be presented for the pr oportion  of subjects in each category by group and study day.  
For the time from randomization to first occurrence of respiratory failure or death on study due 
to any cause, the Kaplan -Meier method will be applied. Subjects will be censored at the time of 
last follow -up. For each group, the 25th percentile, median and 75th percentile will be presented, 
if possible. Possible differences between groups will be assessed by the log -rank test.  
The total number of deaths per group will be presented for All -cause mortality at Day 90.  
9.4.6.  Exploratory Endpoints  
For all other efficacy endpoints, descriptive statistics (number of subjects, mean, standard 
deviation, minimum, median and maximum values) wil l be presented by group and study day. 
The changes or percent changes from Day 1 to each subsequent day will be calculated for each 
subject and descriptive statistics will be presented. Possible differences between groups will be 
assessed using a MMRM analysis of variance \covariance. The model will include fixed effects of 
group, study day and group -by-study day interaction with subject as a random effect. The Day 1 
value will be included when appropriate.  
9.4.7.  Interim Analysis  
An interim futility analysis will be performed after 40 subjects have been enrolled. The analysis 
will be performed by an independent biostatistician who will have no contact with the study 
team.  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 37 of 49
  10. ADVERSE EVENT DEFINITIONS AND PROCEDURE FOR 
RECORDING, EVALUATING, FOLLOW -UP AND REPORTING  
10.1. Mon itoring, Recording and Reporting of Adverse Events  
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may 
appear or worsen in a subject  during the course of a study.  It may be a new intercurrent illness, a 
worsening conc omitant illness, an injury, or any concomitant impairment of the subject ’s health, 
including laboratory test values (as specified by the criteria below), regardless of etiology.  Any 
worsening (i .e., any clinically significant adverse change in the frequen cy or intensity of a pre -
existing condition) should be considered an AE.  A diagnosis or syndrome should be recorded on 
the AE page of the CRF rather than the individual signs or symptoms of the diagnosis or 
syndrome.  
An overdose, accidental or intentional , whether or not it is associated with an AE, or abuse, 
withdrawal, sensitivity or toxicity to a n investigational product should be reported as an AE.  If 
an overdose is associated with an AE, the overdose and AE should be reported as separate terms.  
All subject s will be monitored for AEs during the study.  Assessments may include monitoring 
of any or all of the following parameters:  the subject ’s clinical symptoms, laboratory, 
pathological, radiological or surgical findings, physical examination findings, or findings from 
other tests and/or procedures.  
All AEs will be recorded by the Investigator from the time the subject  signs informed consent 
until 28 days after hospital discharge .  AEs that lead to study discontinuation should be fo llowed 
until resolution or stabilization.  
Serious Adverse Events (SAEs), regardless of relationship to investigational product , that occur 
from the time the subject  signs informed consent until the last study visit  and those made known 
to the Investigator  at any  time thereafter must be reported to Drug Safety within  24 hours of the 
Investigator’s knowledge of the event.  
10.2. Evaluation of Adverse Events  
A qualified Investigator will evaluate all adverse events as to:  
10.2.1.  Seriousness  
A serious adverse event (SAE) is any AE occurring at any dose that:  
• Results in death;  
• Is life -threatening (ie, in the opinion of the Investigator, the subject  is at immediate 
risk of death from the AE);  
• Requires inpatient hospitalization or prolongation of existing hospitalization 
(hospitalization is defined as an inpatient admission, regardless of length of stay);  
• Results in persistent or significant disability/incapacity (a substantial disruption of the 
subject ’s ability to conduct normal life functions);  
• Is a cong enital anomaly/birth  defect;  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 38 of 49
  • Constitutes an important medical event.  
Important medical events are defined as those occurrences that may not be immediately life 
threatening or result in death, hospitalization, or disability, but may jeopardize the subject  or 
require medical or surgical intervention to prevent one of the other outcomes listed above.  
Medical and scientific judgment should be exercised in deciding whether such an AE should be 
considered serious.  
Events not considered  to be SAEs are hospitaliza tions for:  
• A standard procedure for protocol therapy administration.  However, hospitalization 
or prolonged hospitalization for a complication of therapy administration will be 
reported as an SAE.  
• Routine treatment or monitoring of the studied indication n ot associated with any 
deterioration in condition.  
• The administration of blood or platelet transfusion as routine treatment of studied 
indication.  However, hospitalization or prolonged hospitalization for a complication 
of such transfusion remains a repor table SAE.  
• A procedure for protocol/disease -related investigations (eg, surgery, scans, 
endoscopy, sampling for laboratory tests, bone marrow sampling).  However, 
hospitalization or prolonged hospitalization for a complication of such procedures 
remains a reportable SAE.  
• Hospitalization or prolongation of hospitalization for technical, practical, or social 
reasons, in absence of an AE.  
• A procedure that is planned (ie, planned prior to starting of treatment on study); must 
be documented in the source documen t and the eCRF.  Hospitalization or prolonged 
hospitalization for a complication remains a reportable SAE.  
• An elective treatment of or an elective procedure for a pre -existing condition 
unrelated to the studied indication.  
• Emergency outpatient treatment or  observation that does not result in admission, 
unless fulfilling other seriousness criteria above.  
If an AE is considered serious, both the AE page/screen of the eCRF and the SAE Report Form 
must be completed.  
For each SAE, the Investigator will provide i nformation on severity, start and stop dates, 
relationship to investigational product , action taken regarding investigational product , and 
outcome.  
10.2.2.  Severity / Intensity  
For both AEs and SAEs, the Investigator must assess the severity/intensity of the event . 
The severity of AEs will be graded based upon the subject ’s symptoms according to CTCAE  
version 5.0  with unique clinical descriptions of severity for each AE based on this general 
guideline:  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 39 of 49
  • Grade 1 = Mild –asymptomatic or mild symptoms; clinical or diag nostic observations 
only; intervention not indicated  
• Grade 2 = Moderate – minimal, local or noninvasive intervention indicated; limiting 
age-appropriate instrumental activities of daily living (ADL)  
• Grade 3 = Severe  or medically significant but not immedia tely life -threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting self -
care ADL  
• Grade 4 = Life-threatening consequences; urgent intervention indicated.  
• Grade 5 = Death related to AE.  
The term “severe” is often used t o describe the intensity of a specific event (as in mild, moderate 
or severe myocardial infarction); the event itself, however, may be of relatively minor medical 
significance (such as severe headache).  This criterion is not the same as “serious” which is  
based on subject /event outcome or action criteria associated with events that pose a threat to a 
subject ’s life or functioning.  
Seriousness, not severity, serves as a guide for defining regulatory obligations.  
10.2.3.  Causality  
An Investigator who is qualified in medicine must make the determination of relationship to the 
investigational product for each AE (Unrelated, Possibly Related or Probably Related).  The 
Investigator should decide whether, in his or her medical judgment, there is a reasonable 
possibility that the event may have been caused by the investigational product.  If no valid reason 
exists for suggesting a relationship, then the AE should be classified as “unrelated.”  If there is 
any valid reason, even if undetermined, for suspecting a possible cause -and-effect relationship 
between the investigational product and the occurrence of the AE, then the AE should be 
considered “related.”  
If the relationship between the AE/SAE and the investigational product is determined to be 
“possible” or “p robable” the event will be considered to be related to the investigational product 
for the purposes of expedited regulatory reporting.  
10.2.4.  Duration  
For both AEs and SAEs, the Investigator will provide a record of the start and stop dates of the 
event.  
10.2.5.  Action T aken  
The Investigator will report the action taken with investigational product  as a result of an AE or 
SAE, as applicable (e .g., discontinuation, interruption, or reduction of study treatment, as 
appropriate) and report if concomitant and/or additional tr eatments were given for the event.   
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 40 of 49
  10.2.6.  Outcome  
All SAEs that have not resolved upon discontinuation of the subject ’s participation in the study 
must be followed until recovered, recovered with sequelae, not recovered or death (due to the 
SAE ).  
10.3. Abnormal Labor atory Values  
An abnormal laboratory value is considered to be an AE if the abnormality:  
• results in discontinuation from the study;  or 
• requires treatment, modification/ interruption of study treatment dose, or any other 
therapeutic intervention; or  
• is judge d to be of significant clinical importance  
Regardless of severity grade  (per CTCAE version 5.0) , only laboratory abnormalities that fulfill 
a seriousness criterion need to be documented as a serious adverse event.  
If a laboratory abnormality is one compone nt of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page/screen of the CRF.  If the abnormality was not a 
part of a diagnosis or syndrome, then the laboratory abnormality should be recorded as the AE.  
If possibl e, the laboratory abnormality should be recorded as a medical term and not simply as an 
abnormal laboratory result (eg, record thrombocytopenia rather than decreased platelets).  
Adverse Laboratory values that also meet the definition of SERIOUS, will be re ported as SAE s. 
10.4. Pregnancy  
All pregnancies or suspected pregnancies occurring in either a female subject  of childbearing 
potential or partner of childbearing potential of a male subject  are immediately reportable events.  
10.4.1.  Females of Childbearing Potential  
Pregnancies and suspected pregnancies (including elevated β -hCG or positive pregnancy test in a 
female of childbearing potential regardless of disease state) occurring while the subject  is on 
investigational product , or within 1 month after last dose of investigational product , are 
considered immediately reportable events.  Investigational product  is to be discontinued 
immediately.  The pregnancy, suspected pregnancy, or positive pregnancy test must be reported 
Drug Safety immediatel y.   
The female subject  should be referred to an obstetrician -gynecologist, preferably one 
experienced in reproductive toxicity for further evaluation and counseling.  The Investigator will 
follow the female subject  until completion of the pregnancy and must notify Drug Safety 
immediately about the outcome of the pregnancy (either normal or abnormal outcome).  
If the outcome of the pregnancy was abnormal (e .g., spontaneous abortion), the Investigator 
should report the abnormal outcome as an AE.  If the abnormal outcome meets any of  the serious 
criteria, it must be reported as an SAE to Drug Safety by facsimile, or other appropriate method, 
within 24 hours of the Investigator’s knowledge of the event using the SAE Report Form  or 
approved equivalent form . 
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 41 of 49
  All neonatal deaths that occu r within 28 days of birth should be reported, without regard to 
causality, as SAEs.  In addition, any infant death after 28 days that the Investigator suspects is 
related to the in -utero exposure to the investigational product  should also be reported to Dr ug 
Safety  within 24 hours of the Investigator’s knowledge of the event.  
10.4.2.  Male Subject s 
If a female partner of a male subject  taking investigational product becomes  pregnant  at any time 
up to one month after the male subject’s last dose of IP , the male subject  taking investigational 
product should notify the Investigator, and the pregnant female partner should be advised to call 
their healthcare provider immediately.  
10.5. Reportin g of Serious Adverse Events  
Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in 
addition to being recorded on the AE page/screen of the CRF.  All SAEs must be reported to the 
Sponsor or the Sponsor’s representative  within 24 hours of the Investigator’s knowledge of the 
event by facsimile, or other appropriate method, using the SAE Report Form, or approved 
equivalent form.  This instruction pertains to initial SAE reports as well as any follow -up reports.  
The Investiga tor is required to ensure that the data on these forms is accurate and consistent.   
This requirement applies to all SAEs (regardless of relationship to investigational product ) that 
occur from the time the subject  signs informed consent until the last stud y visit and those made 
known to the Investigator at anytime thereafter that are suspected of being related to  
investigational product .  ALL SAEs occurring prior to treatment (after signing the ICF) will be 
captured.  
The SAE report should provide a detailed  description of the SAE and include a concise summary 
of hospital records and other relevant documents.  If a subject  died and an autopsy has been 
performed, copies of the autopsy report and death certificate are to be sent to the Sponsor or the 
Sponsor’s representative  as soon as these become available.  Any follow -up data should be 
detailed in a subsequent SAE Report Form, or approved equivalent form, and sent to the Sponsor 
or the Sponsor’s representative.  
Where required by local legislation, the Investi gator is responsible for informing the Institutional 
Review Board ( IRB)/Ethics Committee ( EC) of the SAE and providing them with all relevant 
initial and follow -up information about the event.  The Investigator must keep copies of all SAE 
information on file including correspondence with the Sponsor or the Sponsor’s representative  
and the IRB/EC.  
10.6. Expedited Reporting of Adverse Events  
For the purpose of regulatory reporting, the Sponsor  will determine the expectedness of events 
suspected of being related to STI-5656  based on the Investigator Brochure  and determine 
regulatory reporting according to l ocal Health Authority  requirements  and according to the 
Safety Management Plan for the protocol.  
Events of e.g. disease progression for the disease under study (including deaths due to disease 
progression for indications that are considered to be fatal) wi ll be assessed but will not be usually 
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 42 of 49
  reported as expedited safety reports to regulatory authorities unless they otherwise meet the 
requirements for expedited reporting.  
Where required by local legislation, the Investigator shall notify his/her IRB/EC pro mptly of new 
serious and unexpected AE(s) or significant risks to subject s communicated by the Sponsor . 
The Investigator must keep copies of all pertinent safety information on file including 
correspondence with Drug Safety  and the IRB/EC.  
Sponsor or Spons or’s representative  Contact Information  for SAE reporting : 
Please refer to the Serious Adverse Event Report Form . 
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 43 of 49
  11. DIRECT ACCESS TO SOURCE DATA/DOCUMENTS  
11.1. Study Monitoring  
Before an investigational site can enter a subject  into the study, a representative of  the Sponsor 
will pre-qualify  the investigational study site to : 
• Determine the adequacy of the facilities  
• Discuss with the Investigator (s) and other personnel their responsibilities with regard to 
protocol adherence, and the responsibilities of the Sponsor  or its representatives.  This 
will be documented in a Clinical Study Agreement between the Sponsor and the 
Investigator . 
As this study will be taking place during the COVID -19 pandemic, it is anticipated that most/ all 
monitoring visits performed will be done remotely.  This study will rely on the use of 
technology, either video or still camera pictures, to confirm facility r equirements.  The video or 
photo files will be stored in the Trial Master File.  
During the study, a monitor from the Sponsor or  its representative will have regular contacts with 
the investigational site, for the following:  
• Provide information and support  to the Investigator (s) 
• Confirm that facilities remain acceptable  
• Confirm that the investigational team is adhering to the protocol, that data are being 
accurately recorded in the case report forms, and that IP accountability checks are being 
performed  
• Perform source data verification.  This includes a comparison of the data in the case 
report forms with the subject ’s source  records.  This will require electronic  access to all 
source  records for each subject . 
• Record and report any protocol deviations not pr eviously sent to the Sponsor or it’s 
representative . 
• Confirm AEs and SAEs have been properly documented on CRFs and confirm any SAEs 
have been forwarded to  the Sponsor or it’s representative  and those SAEs that met 
criteria for reporting have been forwarde d to the IRB.  
The monitor will be available between visits if the Investigator (s) or other staff needs 
information or advice.  
11.2. Audits and Inspections  
Authorized representatives of the Sponsor , a regulatory authority, an Independent Ethics 
Committee or an In stitutional Review Board may visit the site to perform audits or inspections, 
including source data verification.  The purpose of audit or inspection by the  Sponsor or its 
representative is to systematically and independently examine all study -related acti vities and 
documents to determine whether these activities were conducted, and data were recorded, 
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 44 of 49
  analyzed, and accurately reported according to the protocol, Good Clinical Practice guidelines of 
the International Conference on Harmonization, and any appl icable regulatory requirements.  
The Investigator should contact the Sponsor  immediately if contacted by a regulatory agency 
about an inspection.  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 45 of 49
  12. QUALITY CONTROL AND QUALITY ASSURANCE  
To ensure compliance with Good Clinical Practices and all applicable reg ulatory requirements, 
the Sponsor or its representative  may conduct a quality assurance audit.  Please see Section  11.2 
for more details regarding the audit process.  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 46 of 49
  13. ETHICS  
13.1. Ethics Review  
The final study protocol, including the final version of the Informed Consent Form  (ICF) , must 
be approved or given a favorabl e opinion in writing by an IRB or IEC as appropriate.  The 
Investigator must submit written approval to the Sponsor or its representative  before he or she 
can enroll any subject  into the study.  
The Principal Investigator is responsible for informing the IR B or IEC of any amendment to the 
protocol in accordance with local requirements.  In addition, the IRB or IEC must approve all 
advertising used to recruit patients/ subject s for the study.  The protocol must be re -approved by 
the IRB or IEC upon receipt of amendments and annually, as local regulations require.  
The Principal Investigator is also responsible for providing the IRB with reports of any 
reportable serious adverse drug reactions from any other study conducted with the IP.  The 
Sponsor or its repres entative  will provide this information to the Principal Investigator.  
Progress reports and notifications of serious adverse drug reactions will be provided to the IRB 
or IEC according to local regulations and guidelines.  
13.2. Ethical Conduct of the Study  
The st udy will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with ICH/Good Clinical Practice, applicable 
regulatory requirements and the Sponsor’s  policy on Bioethics.  
13.3. Written Informed  Consent  
The Principal Investigator will ensure that the subject  is given full and adequate oral and written 
information about the nature, purpose, possible risk and benefit of the study.  Subject s must also 
be notified that they are free to discontinue fr om the study at any time.  The subject  should be 
given the opportunity to ask questions and allowed time to consider the information provided.  
The subject ’s signed and dated informed consent must be obtained before conducting any study 
procedures.  
The Prin cipal Investigator must maintain the original, signed ICF.  A copy of the signed ICF 
must be given to the subject . 
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 47 of 49
  14. APPENDICES  
14.1. List of Abbreviations and Definitions of Terms  
The following abbreviations and specialist terms are used in this study protocol.  
Table  3: Abbreviations  
Abbreviation  Explanation  
ADL  Activities of daily living  
AE Adverse Events  
ALC  Absolute lymphocyte count  
ALT  Alanine aminotransferase  
AST  aspartate aminotransferase  
Β-hCG  Beta human chorionic gonadotropin  
CONSORT  Consolidated Standards of Reporting Trials  
COVID -19 Coronavirus 2019  
CRP  C-reactive protein  
CTCAE  Common Terminology Criteria for Adverse Events , Version 5.0  
DMC  Data monitoring committee  
EC Ethics Committee  
ECG  Electrocardiogram  
ECMO  Extracorporeal membrane oxygenation  
e-CRF  Electronic case report form  
ET Early Termination  
F Fahrenheit  
FA Full analysis  
FDA  Food and Drug Administration  
FCBP  Female of child -bearing potential  
FiO 2 Fraction of inspired oxygen  
FSH Follicle stimulating hormone  
G Grade  
ICF Informed consent form  
ICH International Council for Harmonisation  
ICU Intensive Care Unit  
IRT Interactive Response Technology  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 48 of 49
  Abbreviation  Explanation  
JAK Janus kinase  
L/min  Liters per minute  
MedDRA  Medical Dictionary for Regulatory Activities  
mIU Milli international units  
mL Milliliters  
PaO 2 Partial pressure of oxygen in arterial blood  
PI3K  Phosphoinositide 3 kinase  
p.o. By mouth  
PP Per protocol  
PT Preferred term  
QD Once daily  
RBC  Red blood cells  
Rbc/hpf  Red blood cells per high power field  
RRT  Rapid response team  
RT-PCR  Reverse transcriptase polymerase chain reaction  
SAE  Serious adverse event  
SARS -CoV -2 severe acute respiratory syndrome coronavirus 2  
SAS Statistical Analysis System  
SOA  Schedule of Assessments  
SOC  Standard of Care  
SOC  System organ class  
SOP Standard operating procedures  
TEAE  Treatment -emergent adverse events  
ULN  upper limit of normal  
VEGF  Vascular endothelial growth factor  
WBC  White blood cells  
WHO  World Health Organization  
 
  
Sorrento Therapeutics, Inc.  
STI-5656 (Abivertinib Maleate)   Protocol STI -5656 -2001 
Confidential   Page 49 of 49
  14.2. Ordinal Scale for Clinical Improvement  
 
Source:  https://www.who.int/blueprint/priority -diseases/key -action/COVID -
19_Treatment_Trial_Design_Master_Protocol_ synopsis_Final_18022020.pdf  
 
